Bristol/Pfizer Offer Some Good Apixaban Results, With Key Study Against Warfarin On Track To Report 2H 2011
This article was originally published in Pharmaceutical Approvals Monthly
Bristol-Myers Squibb/Pfizer got incremental good news and a nice addition to the safety database for their experimental anticoagulant apixaban when a Phase III study was ended early for efficacy at preventing stroke compared to aspirin. The next big read-out for the oral Factor Xa inhibitor, though, will be in the first half of 2011, when results of a major head-to-head contest against warfarin in that setting are due
You may also be interested in...
The attributes of Merck/Portola's Factor Xa inhibitor betrixaban, and where it fits in the crowded development space of novel anticoagulants, came into sharper focus with the release of new Phase II data at the American College of Cardiology annual meeting
With the positive results of the ADVANCE II study of Bristol-Myers Squibb/Pfizer's apixaban now offsetting the failed non-inferiority of the earlier ADVANCE I study, the ADVANCE III study is shaping up to be the tie-breaker for how the investigational anticoagulant stacks up against Sanofi-Aventis' low molecular weight heparin Lovenox (enoxaparin) in patients undergoing orthopedic surgery
Bayer/J&J Will Resubmit Xarelto For Acute Indication In Second Half, Along With New Application For Chronic Use
Bayer/J&J plan to file the first chronic indication for their anticoagulant Xarelto, as well as respond to FDA on the "complete response" letter for their application for acute use in hip and knee replacement surgery, in the second half of 2010, Bayer CEO Werner Wenning announced Feb. 26 during the firm's 2009 year-end report